A collage of Michael Klichinsk and Carisma Therapeutics
Jun 27, 2024, 12:32
Michael Klichinsky: Carisma Therapeutics received FDA Fast Track Designation for CT-0525
Michael Klichinsky, Co-Founder and Chief Scientific Officer at Carisma Therapeutics, shared on LinkedIn:
“We are excited to share that Carisma Therapeutics received FDA Fast Track Designation for CT-0525 for the treatment of advanced HER2-overexpressing solid tumors.
More information here.”
Source: Michael Klichinsky/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 22, 2024, 09:04
Dec 22, 2024, 07:59
Dec 22, 2024, 07:55
Dec 22, 2024, 07:44